ストックスクリーナーアプリを入手
5.0374
0.30%
0.0474
前日終値:
$4.99
開ける：
$4.99
24時間の取引高:
18,305
Relative Volume:
0.01
時価総額：
$472.69M
収益：
$824.50M
当期純損益:
$-365.90M
株価収益率:
-1.2743
EPS:
-3.9531
ネットキャッシュフロー:
$-25.60M
1週間 パフォーマンス:
-3.56%
1か月 パフォーマンス:
+9.28%
6か月 パフォーマンス:
-36.32%
1年 パフォーマンス:
-32.64%
1日の値動き範囲:
$4.985
$5.06
1週間の範囲:
$4.91
$5.31
52週間の値動き範囲:
$3.76
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
名前
Myriad Genetics Inc
セクター
電話
801-584-3600
住所
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
5.005 | 471.27M | 824.50M | -365.90M | -25.60M | -3.9531 |
TMO
Thermo Fisher Scientific Inc
|
529.26 | 194.94B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
193.51 | 137.69B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.36 | 45.19B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
122.69 | 34.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
337.61 | 32.91B | 3.17B | 642.63M | 516.49M | 10.77 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-21 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 開始されました | Craig Hallum | Buy |
| 2024-12-10 | 開始されました | UBS | Neutral |
| 2024-12-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Underperform |
| 2024-05-08 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 再開されました | Piper Sandler | Neutral |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Underweight |
| 2023-05-23 | アップグレード | Goldman | Sell → Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 開始されました | Stephens | Equal-Weight |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Sell |
| 2019-09-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-07-29 | ダウングレード | Needham | Strong Buy → Hold |
| 2019-07-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-03-12 | 繰り返されました | Needham | Strong Buy |
| 2019-01-03 | 開始されました | Needham | Strong Buy |
| 2018-11-30 | アップグレード | Goldman | Sell → Neutral |
| 2018-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 開始されました | Goldman | Sell |
| 2018-01-22 | 繰り返されました | Barclays | Equal Weight |
| 2018-01-05 | 開始されました | BTIG Research | Buy |
| 2017-10-02 | 再開されました | Leerink Partners | Mkt Perform |
| 2017-08-09 | 繰り返されました | Barclays | Equal Weight |
| 2017-02-08 | アップグレード | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 開始されました | Deutsche Bank | Sell |
| 2016-10-10 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
すべてを表示
Myriad Genetics Inc (MYGN) 最新ニュース
EPO Biomarkers Market Outlook 2026-2033: Growth Drivers, - openPR.com
Myriad (MYGN) up 4.1% since last earnings report: Can it continue? - MSN
Myriad Genetics (MYGN) to Present at AACR Annual Meeting 2026 - GuruFocus
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 - ChartMill
Myriad Genetics, Inc. (NASDAQ:MYGN) Sees Significant Decline in Short Interest - MarketBeat
Myriad Genetics (NASDAQ: MYGN) COO has 1,069 shares withheld for RSU taxes - Stock Titan
Tax withholding trims Myriad Genetics (MYGN) CSO stake by 946 shares - Stock Titan
Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by TD Cowen - MarketBeat
[ARS] MYRIAD GENETICS INC SEC Filing - Stock Titan
Myriad Genetics (NASDAQ: MYGN) sets 2026 votes and outlines cancer-focused growth - Stock Titan
Myriad Genetics Expands MyChoice Test Access for Prostate Cancer Patients in Japan - National Today
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan - Bitget
GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026 - Yahoo Finance
Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y - MSN
Japan clears Myriad test for prostate cancer patients using Lynparza - Stock Titan
Sectors Review: What is the next catalyst for Myriad Genetics IncPortfolio Return Report & Low Risk High Reward Ideas - baoquankhu1.vn
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now? - MSN
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Lobbying Update: $30,000 of TIBER CREEK GROUP ON BEHALF OF MYRIAD GENETICS INC. lobbying was just disclosed - Quiver Quantitative
Myriad Genetics Underscores Commitment to Cancer Care - GlobeNewswire
Aberdeen Group plc Purchases 246,748 Shares of Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad brings 4 SGO studies, including ovarian recurrence data - Stock Titan
Can Myriad Genetics Inc maintain its current growth rate2026 Opening Moves & Long Hold Capital Preservation Tips - baoquankhu1.vn
Trend Report: Can Myriad Genetics Inc maintain its current growth rate2026 Opening Moves & Long Hold Capital Preservation Tips - baoquankhu1.vn
Market Outlook: Whats next for Myriad Genetics Inc stockMarket Trend Report & AI Optimized Trade Strategies - baoquankhu1.vn
MYGN Technical Analysis | Trend, Signals & Chart Patterns | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - Yahoo Finance UK
Myriad Genetics | SCHEDULE 13G/A: Others - Moomoo
BlackRock (NYSE: MYGN) holds 7.98M shares, 8.5% stake reported - Stock Titan
Myriad Genetics Q4 2025 Results: Revenue Beat, Raised GuidanceNews and Statistics - IndexBox
Myriad Genetics And 2 Other Penny Stocks To Watch Closely - Yahoo Finance
Myriad Genetics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Myriad Genetics: Market Pricing in Failure as Catalysts Build for Re-Rating - Bitget
Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Myriad Genetics Inc (MYD.HA) Stock Price, News, Quote & History - ca.finance.yahoo.com
3 Healthcare Stocks with Open Questions - Yahoo Finance
Myriad Genetics: SOTP Suggests The Company Is Undervalued - Seeking Alpha
Myriad Genetics, Inc. (MYD.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know - Yahoo Finance
Vanguard (MYGN) amendment shows 0 shares; subsidiaries disaggregate holdings - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Myriad Genetics launches Prequel Prenatal Screen using AMPLIFY technology for early chromosomal risk detection - Traders Union
Myriad Genetics (MYGN) CSO has shares withheld to cover RSU taxes - Stock Titan
Myriad Genetics (MYGN) COO has 2,055 shares withheld to cover taxes - Stock Titan
Myriad Genetics Inc (MYGN) 財務データ
収益
当期純利益
現金流量
EPS
0.26%
0.02%
大文字化:
|
ボリューム (24 時間):